Drug Development Pipeline
| Clinical Trial Candidate | Preclinical | IND | Phase I | ||
|---|---|---|---|---|---|
| Deltacel-01 Deltacel™ in combination with Low-Dose Radiation Allogeneic, Non-Viral, Non-engineered off-the-shelf GDT therapy |
Universal Non-Engineered | NSCLC | First patient Nov 2023 |
||
| Isocel™ Alone or in combination with Low-Dose Radiation* Allogeneic, off-the-shelf, Viral vector-free GDT CAR-T therapy |
Mesothelin Isoform KRBP Proprietary Target |
OC, MPM, PAAD | H2 2025 |
||
| Procel™ Alone or in combination with Low-Dose Radiation* Allogeneic, off-the-shelf, GDT CAR-T therapy |
PDL-1 | Multi-indication, PDL-1+ tumors |
2026 |
| Clinical Trial Candidate | Target | Progress |
|---|---|---|
| Deltacel-01 Deltacel™ in combination with Low-Dose Radiation Allogeneic, Non-Viral, Non-engineered off-the-shelf GDT therapy |
Universal Non-Engineered NSCLC |
First patient Nov 2023 FTD Aug 2024 Expansion phase started in Sep 2024 |
| Isocel™ Alone or in combination with Low-Dose Radiation* Allogeneic, off-the-shelf, Viral vector-free GDT CAR-T therapy |
Mesothelin Isoform KRBP Proprietary Target OC, MPM, PAAD |
H2 2025 |
| Proce™ Alone or in combination with Low-Dose Radiation* Allogeneic, off-the-shelf, GDT CAR-T therapy |
PDL-1 Multi-indication, PDL-1+ tumors |
2026 |
Subject to obtaining sufficient financing to support the progression of the development of our clinical trial candidates.
*This program may result in two clinical trials, one with and one without low-dose radiation, depending on the pre-clinical evidence.
Last Updated: 10/2024
Download Kiromic’s Expanded Access Policy for DeltacelTM
R&D Strategy
Expand Tumor Target Recognition
DIAMOND AI™bioinformatics can screen, prioritize, and harmonize novel surface tumor targets:
- Analysis of public and proprietary data bases to expand tumor target data analytics
- Identify alternatively spliced targets, leading to the potential discovery of novel 1st and 2nd-line targets